Share Name Share Symbol Market Type Share ISIN Share Description
Nuformix Plc LSE:NFX London Ordinary Share GB00BYW79Y38 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 1.30 1,118,875 08:00:03
Bid Price Offer Price High Price Low Price Open Price
1.25 1.35 1.30 1.30 1.30
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Nonequity Investment Instruments 0.20 -1.38 -0.22 8
Last Trade Time Trade Type Trade Size Trade Price Currency
15:02:01 O 14,839 1.2875 GBX

Nuformix (NFX) Latest News

More Nuformix News
Nuformix Investors    Nuformix Takeover Rumours

Nuformix (NFX) Discussions and Chat

Nuformix Forums and Chat

Date Time Title Posts
18/9/202108:49Nuformix plc7,756

Add a New Thread

Nuformix (NFX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Nuformix trades in real-time

Nuformix (NFX) Top Chat Posts

Nuformix Daily Update: Nuformix Plc is listed in the Nonequity Investment Instruments sector of the London Stock Exchange with ticker NFX. The last closing price for Nuformix was 1.30p.
Nuformix Plc has a 4 week average price of 1.28p and a 12 week average price of 1.28p.
The 1 year high share price is 4.30p while the 1 year low share price is currently 1.28p.
There are currently 591,609,368 shares in issue and the average daily traded volume is 2,403,976 shares. The market capitalisation of Nuformix Plc is £7,690,921.78.
david gruen: RNS Number : 4839L Nuformix PLC 13 September 2021 13 September 2021 Nuformix plc ("Nuformix" or the "the Company") Worldwide licensing agreement with Oxilio for NXP001 Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce that it has signed an exclusive global licensing agreement with Oxilio Ltd ("Oxilio"), a privately held pharmaceutical development company, for NXP001 (a proprietary new form of aprepitant) for oncology indications. Under the terms of the licensing agreement, Oxilio has obtained an exclusive licence to research, develop and commercialise NXP001 globally for oncology indications. Nuformix is eligible to receive an undisclosed upfront payment, development milestone payments and a royalty on net sales, capped at GBP2 million per annum. -- On 23 September 2020, Nuformix granted an exclusive option to Oxilio to license NXP001 globally for oncology indications. This triggered an undisclosed upfront payment. -- On 22 March 2021, Oxilio exercised its option to acquire a licence for NXP001. Oxilio and Nuformix then began working together to finalise an exclusive global licensing agreement for NXP001. Dr Anne Brindley, CEO of Nuformix, said: "We are delighted to complete the licensing agreement with Oxilio - achieving this exclusive global licensing deal for NXP001 in oncology is a major step forward as it validates the Nuformix technology and intellectual property, and also endorses our strategy of repurposing drugs and licensing at an early stage. Nuformix will now concentrate on developing its two lead assets NXP002 and NXP004." Dr Simon Yaxley, Co-Founder and Director of Oxilio said: "We are pleased to expand our clinical development pipeline with the licensing of NXP001, which is highly complementary to our strategy of identifying, repurposing and commercialising existing drugs to address unmet needs in cancer therapy . NXP001 , a novel form of aprepitant with improved properties, and its Phase 1 study demonstrates the potential for improved bioavailability without needing a complex formulation. Our hope is for the consolidated efforts under the agreement to enable Oxilio to accelerate the development of NXP001 and bring new treatment options to a broad range of cancer patients."
whocares765: Get in lovely NFX dealNow over 2p pleaseHTTPS://www.twitter.com/DVH_Phoenix/status/1437298053648637953
spurs90: It’s not nfx but it’s a preclinical study that shows inhalation is better than intravenously injections in the vein In preclinical studies, PRS-220, Pieris Pharmaceuticals’ experimental inhaled therapy for idiopathic pulmonary fibrosis (IPF), showed stronger lung tissue penetration and anti-scarring effects than pamrevlumab — an into-the-vein, mechanistically similar IPF therapy currently being tested in a Phase 3 clinical trial. These promising findings, which support Pieris’ plans to launch a Phase 1 trial of PRS-220 next year, were presented in a poster titled, “Development of PRS-220, a potential best-in-class, inhaled CTGF/CCN2 inhibitor for the treatment of IPF,” at the European Respiratory Society International Congress 2021, held virtually Sept. 5–8. “PRS-220 exemplifies our respiratory strategy of advancing programs addressing clinically-validated targets where a local approach may provide significant benefit to patients,” Shane Olwill, PhD, Pieris’ chief development officer, said in a press release. Connective tissue growth factor (CTGF) is a protein found at higher-than-normal levels in the lung tissue of people with IPF. It contributes to the progressive and excessive tissue scarring (fibrosis) characteristic of the disease. As such, therapeutic approaches suppressing CTGF are thought to have the potential to prevent the activation of downstream pro-inflammatory and pro-fibrotic factors, thereby slowing or halting IPF progression. In agreement, pamrevlumab — FibroGen’s experimental anti-CTGF antibody that is delivered directly into the bloodstream — was shown to safely and effectively slow lung function decline in IPF patients in a Phase 2 trial (NCT01890265). Https://pulmonaryfibrosisnews.com/2021/09/08/inhaled-prs-220-superior-into-the-vein-pamrevlumab-idiopathic-pulmonary-fibrosis-ipf-preclinical-data/
sentiment riles: Opti is falling Nfx rising I don’t need to check I just wait for the scum troll posts 😂
spurs90: They got Julian Higgins holding and date threshold crossed right? Julian Higgins 2.54% Shares 15,000,000 Value £210.0k Change % -36.17% Portfolio % 0% Last Reported 07 Jun 21 Https://simplywall.st/stocks/gb/pharmaceuticals-biotech/lse-nfx/nuformix-shares
spurs90: Top 25 shareholders own 61.87% of the company Jarvis Securities plc, Asset Management Arm 8.28% HBOS Investment Fund Managers Limited 8.22% High Value Manufacturing Catapult 6.65% Daniel Gooding 6.34% Joanne Holland 6.34% Barclays Bank PLC, Wealth and Investment Management Division 5.32% A J Bell Holdings Limited, Asset Management Arm 3.61% Alan Chorlton 3% IG Group Holdings Plc, Asset Management Arm 2.83% Julian Higgins 2.54% Integrated Financial Arrangements plc, Asset Management Arm 1.28% Equiniti Group Limited, Asset Management Arm 1.12% HSBC Global Asset Management (UK) Limited 0.96% EFG Private Bank SA, Asset Management Arm 0.77% Close Asset Management Limited 0.63% Interactive Brokers Group, Inc., Asset Management Arm 0.6% Charles Stanley & Co. Ltd, Asset Management Arm 0.56% Nomura Holdings Inc, Securities & Investment Arm 0.53% Joh. Berenberg, Gossler & Co. KG, Asset Management Arm 0.52% Redmayne Bentley LLP, Asset Management Arm 0.34% Nordea Investment Management AB 0.34% Investec Wealth & Investment Limited 0.31% Cantor Fitzgerald Asset Management 0.28% Idealing.com, Asset Management Arm 0.27% Peel Hunt LLP., Asset Management Arm 0.23% Https://simplywall.st/stocks/gb/pharmaceuticals-biotech/lse-nfx/nuformix-shares
peverill: If that was the case then maybe they should have kept it quiet,there seems to be an agenda of destroying the share price here at any cost.The RNS this morning was not needed IMHO, a deal collapsing yes, an employee leaving in 6 months,pointless.The management are inept at best.
maytrees: Odd though with so many buys that the share price is not rising again. Still with FTSE100 down c.80 points one can be thankful for small NFX gain Edit: further small gain as I typed.
hollywood6: I hope the rise is due to the innovate grant.If its regarding Oxillo, what is a significant upfront payment? Will it be disclosed? Are you expecting huge share price rises from this? What will it add to the market cap? How will that reflect in the share price?
spurs90: Nfx The rise on Friday imo could be attributed to one of 2 things 1– Innovate UK Grant for the further development of NXP002 which, if successful, would supplement investment and provide important non-dilutive funding for the lead asset 2 - Oxilio oncology option The terms of its option agreement signed in September 2020 with Oxilio cover a licence for the development and exploitation of NXP001 in oncology. Deal terms include an undisclosed up-front payment to NFX offering an exclusive option period of 6 months, within which a global licensing agreement can be agreed, expiring 24 March 2021 VALUATION We evaluate the lead programme and look at recent deals in the IPF space to illustrate the value of NFX and its lead asset as it advances its strategy and/or secures new deals over the next 12-18 months. We use a DCF approach to value the lead programme NXP002 assuming global development and as it approaches key inflection points. We accept that this is the key focus and with the most certainty at present, until there is greater clarity on the way forward for NXP001 and for NXP004. We take into account that the programme is still at an early stage, nevertheless that risk is reduced owing to the existing body of safety data on the underlying drug, and because of the abbreviated regulatory route applicable for repurposed co-crystal or new solid form therapies. For simplicity, we look at the value of the asset as if NFX were to market the product, rather than via a licensing deal, to illustrate its worth to potential licensees. Our valuation of NXP002 as a preclinical asset using a 13% WACC gives a risk adjusted valuation of NFX of £52.8m which is equivalent to 9 pence per share (based on 591.6m shares in issue post funding). This assumes that a Phase I ready package for the asset is in place which is being developed over the next 12-18 months NFX is looking to license the asset before Phase I, in which case we would anticipate a global deal value of between $360-450m, in upfront and milestone payments, plus single digit royalties on sales, increasing in value in proportion to the stage of development of the underlying asset: from feasibility up to the full Phase I ready GLP package, assuming successful outcomes and based on recent precedent. We illustrate a range of deal metrics in IPF to support our assumptions. Industry precedent shows that once a robust patent position is built, even early stage IPF assets are attracting significant deals in the indication. While pipelines are filling out, the novel approach, acute need and the inhaled route of administration are key factors that can differentiate NXP002. NEWSFLOW Over the next 12-18 months there are a number of possible events on the horizon: – Initiation of the feasibility studies on NXP002 in Q2 2021 – OutcomedecisiononOxiliooptiononNXP001. – News on patent filing outcomes, strategic path and partnering for NXP004 in oncology. – Outcome of Innovate UK Grant Application for NXP002 in Q1 2021. – Potential completion (subject to funding) of Phase I ready package for NXP002 by H1 2022. – Partneringnewsacrossthepipeline. – Corporate: FY results 12 months ended 31 March 2021 – date estimated July/August
Nuformix share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210921 21:45:45